ClinicalTrials.gg
CompletedNCT04565678Updated Dec 10, 2020

A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

A Phase 1 interventional study of Mitapivat tablets and Mitapivat coated granules in Healthy Volunteers, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-10.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the relative bioavailability of the mitapivat coated granule formulation compared to the tablet formulation following a single oral dose of mitapivat under fasted conditions in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 32.0 kilograms per square meter (kg/m\^2), inclusive;
  • In good health, determined by no findings from medical history, physical examination, 12-lead (ECG), vital signs measurements, and clinical laboratory evaluations;
  • Females will not be pregnant or lactating, and females of and males will agree to use ;
  • Participant has no clinically significant history or presence of ECG findings as judged by the Investigator at Screening and Check-in.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator;
  • History of significant , intolerance, or allergy to any drug compound, food, including the 2 soft foods administered in this study, or other substance, unless approved by the Investigator;
  • History of stomach or intestinal surgery or resection including cholecystectomy that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed);
  • History of any with the exception of non-melanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
  • Participant has liver function tests including (ALT), aspartate transaminase (AST), alkaline phosphatase, and total that are greater than the at Screening or Check-in;
  • Participant has count or and hematocrit values that are below the lower limit of normal at Screening or Check-in;
  • Confirmed (eg, original value and 2 consecutive repeat measurements) systolic blood pressure >150 or \<90 millimeters of mercury (mmHg), diastolic blood pressure >90 or \<50 mmHg, and pulse rate >100 or \<45 beats per minute (bpm);
  • Confirmed corrected for heart rate using Fridericia's method (QTcF) >450 milliseconds (msec) (male participants) or >470 msec (female participants);
  • History of active alcoholism or drug/chemical abuse within 2 years prior to Check-in;
  • Alcohol consumption of >21 units per week for males and >14 units for females;
  • Positive urine drug screen at Screening or positive alcohol breath test result or positive urine drug screen at Check-in;
  • Positive hepatitis panel and/or positive test;
  • Participants with an active infection requiring systemic antimicrobial therapy, or with an active infection deemed by the Investigator during Screening;
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing (whichever is longer);
  • Participant has used any over-the-counter medications, including herbal or nutritional supplements, within 28 days (or 5 half-lives, whichever is longer) before the first dose of study drug until after the Follow up phone call;
  • Participant has used any prescription (excluding hormone replacement therapy and hormonal ) medications within 30 days (or 5 half-lives, whichever is longer) before the first dose of study drug until after the Follow up phone call;
  • Use of tobacco- or nicotine-containing products including cigarettes, snuff, nicotine patch, nicotine chewing gum, vaporizers, or inhalers, within 6 months prior to Screening until after the Follow up phone call, or positive cotinine at Screening or Check-in;
  • Participant must refrain from marijuana or cannabinol-containing products for 7 days before Screening until after the Follow up phone call;
  • Ingestion of poppy seed within 7 days prior to Check-in until after the Follow up phone call;
  • Participant has consumed grapefruit or grapefruit juice, Seville orange, or Seville orange containing products (eg, marmalade) within 7 days before the first dose of study drug until after the Follow up phone call;
  • Participant has consumed caffeine- or xanthine-containing products within 24 hours prior to first dose of study drug until after the Follow up phone call;
  • Participant has consumed vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, and mustard), or charbroiled meats for 7 days prior to first dose of study drug until after the Follow-up phone call;
  • Participant is involved in strenuous activity or contact sports from 7 days before Check-in until after the Follow-up phone call;
  • Receipt of blood products within 2 months prior to Check-in;
  • Participant has donated blood or blood products >450 milliliters (mL) within 30 days before the first dose of study drug;
  • Participant has a poor peripheral venous access;
  • Have previously completed or withdrawn from this study or any other study investigating mitapivat sulfate, and have previously received the mitapivat sulfate;
  • Participant has a history of allergy to sulfonamides (eg, co-trimoxazole antibiotic, silver sulfadiazine topical antibiotic for burn wounds) that has been characterized by acute hemolytic anemia, drug-induced liver injury, anaphylaxis, rash of erythema multiforme type, or Stevens-Johnson syndrome.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: ABCD

    Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.

    Drug: Mitapivat tablets · Drug: Mitapivat coated granules

  • Experimental
    Treatment Sequence 2: BDAC

    Participants will receive Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 2) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.

    Drug: Mitapivat tablets · Drug: Mitapivat coated granules

  • Experimental
    Treatment Sequence 3: CADB

    Participants will receive Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 1) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 3) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.

    Drug: Mitapivat tablets · Drug: Mitapivat coated granules

  • Experimental
    Treatment Sequence 4: DCBA

    Participants will receive Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 1) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 2) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 3) followed by Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.

    Drug: Mitapivat tablets · Drug: Mitapivat coated granules

Interventions

  • Oral tablets

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

  • Oral coated granules

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Mitapivat Under Fasted Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  2. Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t) of Mitapivat Under Fasted Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  3. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-∞) of Mitapivat Under Fasted Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  4. Time to Reach Maximum Observed Concentration (Tmax) of Mitapivat Under Fasted Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

Secondary outcomes

  1. Cmax of Mitapivat Under Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  2. AUC0-t of Mitapivat Under Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  3. AUC0-∞ of Mitapivat Under Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  4. Tmax of Mitapivat Under Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  5. Relative Bioavailability (Frel) Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  6. Area Under the Plasma Concentration-Time Curve from Time Zero to Twelve Hours (AUC0-12) of Mitapivat Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  7. Apparent Plasma Terminal Elimination Half-life (t½) of Mitapivat Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  8. Apparent Total Plasma Clearance (CL/F) of Mitapivat Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  9. Apparent Volume of Distribution (Vz/F) of Mitapivat Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  10. Apparent Terminal Elimination Rate Constant (λz) of Mitapivat Under Fasted and Fed Conditions

    Time frame: Pre-dose and multiple time points post-dose (up to 72 hours)

  11. Number of Participants With Adverse Event (AEs)

    Time frame: Up to approximately 9 weeks

  12. Number of Participants With AEs, Graded by Severity

    Time frame: Up to approximately 9 weeks

  13. Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values

    Time frame: Up to approximately 9 weeks

  14. Number of Participants With Clinically Significant Abnormal Findings for 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Up to approximately 9 weeks

  15. Number of Participants With Clinically Significant Abnormal Findings for Vital Signs Parameters

    Time frame: Up to approximately 9 weeks

  16. Number of Participants With Clinically Significant Abnormal Physical Examination Findings

    Time frame: Up to approximately 9 weeks

07

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Sep 25, 2020
StartActual
Sep 21, 2020
Primary completionActual
Dec 3, 2020
CompletionActual
Dec 3, 2020
Last update
Dec 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04565678
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Sep 21, 2020
Primary completion
Dec 3, 2020
Completion
Dec 3, 2020
Last update
Dec 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion